NanHua Biology: Intend to acquire 51% equity stake in HuiZe Pharmaceutical, the restructuring is still in progress.

Nanhua Biology announced that on August 12, 2025, the company disclosed its intention to acquire a total of 51% equity stake in Huize Medicine held by Cheng Ze Energy and others. After the completion of the transaction, Huize Medicine will become a subsidiary of Nanhua Biology. This transaction is expected to constitute a significant asset restructuring, does not constitute a related party transaction, does not involve the issuance of shares, and will not result in a change of control. As of the disclosure date of the announcement, the exclusivity period has expired, and all parties are still actively moving forward. The company will continue to carry out due diligence and other work, no formal agreement has been signed yet, the restructuring is still in progress, and there is uncertainty.